Data Sheet 1_The dawn of the dual-target era in respiratory disease: promise, pitfalls, and a roadmap for bispecific antibodies.doc

TSLP/IL-13 bispecifics have progressed into mid-to-late-stage clinical development, with two distinct molecules (lunsekimig and CM512) in Phase II/III and Phase II trials, respectively. Preclinical and early clinical signals indicate that alarmin blockade may extend beyond classical type 2 immunity, offering therapeutic potential in mixed and non-type 2 inflammatory phenotypes.

Yet this molecular acceleration risks outpacing our capacity to deploy these agents rationally. No biomarker-guided framework currently exists to determine which patients require dual-pathway versus single-pathway blockade, or which target pair best matches a given patient’s inflammatory endotype. The central clinical tension is whether the incremental benefit of dual-pathway neutralization justifies any increase in immunosuppressive risk.